Chemours Investors Notified of Securities Fraud Lawsuit and Lead Plaintiff Opportunity

Shareholders who purchased shares of The Chemours Company (NYSE: CC) during the specified class period have been notified by the law firm Schall, Brown & Schwartz LLP regarding a pending securities class action lawsuit. The legal action relates to alleged violations of federal securities laws.

According to the announced details, the lawsuit centers on allegations that the company made false and misleading statements to the market. Specifically, the complaint alleges that Chemours overstated demand for its Opteon products while experiencing slowing demand due to prior-year overselling, and that its fiscal guidance for 2026 was unreliable.

Case Details and Timeline

• Class Period: February 20, 2026, to August 4, 2026
• Filing Firm: Schall, Brown & Schwartz LLP
• Legal Focus: Violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5

Shareholder Options and Next Steps

Investors who suffered financial losses during the class period have the opportunity to contact the firm to discuss potential lead plaintiff appointments.

• Participation as a lead plaintiff is not mandatory to share in any potential recovery.
• The class has not yet been certified by a court.
• Absent action, investors remain unrepresented class members.

Interested parties can verify details and review original announcements directly through the law firm's official channels or by contacting firm representatives Brian Schall or David Schwartz.